Latigo Biotherapeutics Q3 2026 Results: Net Loss of $20.9M, Loss Narrows
Latigo Biotherapeutics is a clinical-stage biopharmaceutical company that has incurred an accumulated deficit of $312.8 million as of September 30, 2026. The company is focused on developing its lead product candidates, onzotrigine and LTG-321, and anticipates continued substantial losses as it funds research and development.
- Key figure
- Net loss $20.9M